38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – October 26-28, 2022
The following summarizes some of the highlights from Day 3 of ECTRIMS 2022.
Latest News
ECTRIMS 2022 HIGHLIGHTS – FRIDAY, OCTOBER 28 EDITION
October 28, 202238th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – October 26-28, 2022
The following summarizes some of the highlights from Day 2 of ECTRIMS 2022.
ECTRIMS 2022 HIGHLIGHTS – THURSDAY, OCTOBER 27 EDITION
October 27, 202238th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – October 26-28, 2022
The following summarizes some of the highlights from Day 1 of ECTRIMS 2022.
Re-evaluating the benefit-risk of high-efficacy treatment in MS
October 3, 2022Click here to take the survey on HE Benefit-risk
The management of multiple sclerosis has begun to shift away from the traditional escalation model – intensifying therapy in response to ongoing disease activity or progression – to one in which high-efficacy DMTs are used earlier in the clinical course. Read More